Synthesis, antimycobacterial evaluation, and molecular docking study of 1,2,4-triazole derivatives

References

• Chakaya J, Petersen E, Nantanda R, Mungai BN, Migliori GB, Amanullah F, Lungu P, Ntoumi F, Kumarasamy N, Maeurer M, et al. The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to end TB. Int J Infect Dis. 2022;124(Suppl. 1):S26–S29.
   PubMedGoogle Scholar
• Klopper M, Warren RM, Hayes C, Gey van Pittius NC, Streicher EM, Müller B, Sirgel FA, Chabula-Nxiweni M, Hoosain E, Coetzee G, et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis. 2013;19(3):449–455.
   PubMed Web of Science ®Google Scholar
• Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Hömke R, Ritter C, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med. 2015;373(20):1986–1988.
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen J, Cui P, Shi W, Shi X, Niu H, Chan D, Yew WW, Zhang W, Zhang Y, et al. Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid. Antimicrob Agents Chemother. 2016;60(4):2542–2544.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Rhee KY. Tuberculosis drug development: history and evolution of the mechanism-based paradigm. Cold Spring Harb Perspect Med. 2015;5(8):a021147.
   PubMed Web of Science ®Google Scholar
• Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. A common mechanism of cellular death induced by bactericidal antibiotics. Cell. 2007;130(5):797–810.
   PubMed Web of Science ®Google Scholar
• Brynildsen MP, Winkler JA, Spina CS, MacDonald IC, Collins JJ. Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production. Nat Biotechnol. 2013;31(2):160–165.
   PubMed Web of Science ®Google Scholar
• Liu C-X, Zhao X, Wang L, Yang Z-C. Quinoline derivatives as potential anti-tubercular agents: synthesis, molecular docking and mechanism of action. Microb Pathog. 2022;165:105507.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wang L, Xia MY, Yang Z-C. Antimycobacterial compound of Cynoglossum lanceolatum Forsk.: bioassay guided isolation, molecular docking, synthesis of analogs, and a plausible mechanism of action. Chem Biodivers. 2023;20:e202200965.
   PubMed Web of Science ®Google Scholar
• Zhang S, Xu Z, Gao C, Ren Q-C, Chang L, Lv Z-S, Feng L-S. Triazole derivatives and their anti-tubercular activity. Eur J Med Chem. 2017;138:501–513.
   PubMed Web of Science ®Google Scholar
• Deb PK, Al-Shar’i NA, Venugopala KN, Pillay M, Borah P. In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis. J Enzyme Inhib Med Chem. 2021;36(1):869–884.
   PubMed Web of Science ®Google Scholar
• Vilchèze C, Jacobs WR Jr. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr. 2014;2(4).
   Google Scholar
• Kinjo T, Koseki Y, Kobayashi M, Yamada A, Morita K, Yamaguchi K, Tsurusawa R, Gulten G, Komatsu H, Sakamoto H, et al. Identification of compounds with potential antibacterial activity against Mycobacterium through structure-based drug screening. J Chem Inf Model. 2013;53(5):1200–1212.
   PubMed Web of Science ®Google Scholar
• Shetye GS, Choi KB, Kim C-Y, Franzblau SG, Cho S. In vitro profiling of antitubercular compounds by rapid, efficient, and nondestructive assays using autoluminescent Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2021;65(8):e0028221.
   PubMed Web of Science ®Google Scholar
• Shu C-C, Liao K-M, Chen Y-C, Wang J-J, Ho C-H. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep. 2019;9(1):11901.
   PubMedGoogle Scholar
• Vilchèze C, Kremer L. Acid-fast positive and acid-fast negative Mycobacterium tuberculosis: the Koch paradox. Microbiol Spectr. 2017;5(2).
   Google Scholar
• Bertrand T, Eady NAJ, Jones JN, Jesmin  , Nagy JM, Jamart-Grégoire B, Raven EL, Brown KA. Crystal structure of Mycobacterium tuberculosis catalase-peroxidase. J Biol Chem. 2004;279(37):38991–38999.
   PubMed Web of Science ®Google Scholar
• Dillon NA, Peterson ND, Feaga HA, Keiler KC, Baughn AD. Anti-tubercular activity of pyrazinamide is independent of trans-translation and rpsA. Sci Rep. 2017;7(1):6135.
   PubMedGoogle Scholar
• Oliveira CG, da S Maia PI, Souza PC, Pavan FR, Leite CQF, Viana RB, Batista AA, Nascimento OR, Deflon VM. Manganese(II) complexes with thiosemicarbazones as potential anti-Mycobacterium tuberculosis agents. J Inorg Biochem. 2014;132:21–29.
   PubMed Web of Science ®Google Scholar
• Orme I. Search for new drugs for treatment of tuberculosis. Antimicrob Agents Chemother. 2001;45:1943.
   PubMed Web of Science ®Google Scholar
• Kapetanaki SM, Zhao X, Yu S, Magliozzo RS, Schelvis JPM. Modification of the active site of Mycobacterium tuberculosis KatG after disruption of the Met–Tyr–Trp cross-linked adduct. J Inorg Biochem. 2007;101(3):422–433.
   PubMed Web of Science ®Google Scholar
• Martin A, Morcillo N, Lemus D, Montoro E, da Silva Telles MA, Simboli N, Pontino M, Porras T, León C, Velasco M, et al. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int J Tuberc Lung Dis. 2005;9:901.
   PubMed Web of Science ®Google Scholar
• Budha NR, Lee RB, Hurdle JG, Lee RE, Meibohm B. A simple in vitro PK/PD model system to determine time-kill curves of drugs against mycobacteria. Tuberculosis. 2009;89(5):378–385.
   PubMed Web of Science ®Google Scholar
• Beers RF Jr, Sizer IW. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem. 1952;195(1):133–140.
   PubMed Web of Science ®Google Scholar
• Marcinkeviciene JA, Magliozzo RS, Blanchard JS. Purification and characterization of the Mycobacterium smegmatis catalase-peroxidase involved in isoniazid activation. J Biol Chem. 1995;270(38):22290–22295.
   PubMed Web of Science ®Google Scholar
• Yurdakok B, Baydan E, Okur H, Gurcan IS. Cytotoxic effects of ethephon and maleic hydrazide in Vero, Hep2, HepG2 cells. Drug Chem Toxicol. 2014;37(4):459–465.
   PubMed Web of Science ®Google Scholar
• Swain SS, Rout SS, Sahoo A, Oyedemi SO, Hussain T. Antituberculosis, antioxidant and cytotoxicity profiles of quercetin: a systematic and cost-effective in silico and in vitro approach. Nat Prod Res. 2022;36:4763.
   PubMed Web of Science ®Google Scholar